Label Changes for:
Twynsta (telmisartan/amlodipine)
November 2011
Changes have been made to the WARNINGS and PRECAUTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
November 2011
WARNINGS AND PRECAUTIONS
Drug Interactions with Amlodipine
- Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.
July 2010
ADVERSE REACTIONS
Clinical Trials Experience
- TWYNSTA tablets: The adverse reactions that occurred in the placebo-controlled factorial design trial in patients treated with Twynsta and at a higher incidence in Twynsta-treated patients (n=789) than placebo-treated patients (n=46) were peripheral edema (4.8% vs 0%), dizziness (3.0% vs 2.2%), and back pain (2.2% vs 0%). Edema (other than peripheral edema), hypotension, and syncope were reported in <2% of patients treated with Twynsta tablets.
- Amlodipine: Gastrointestinal- change of bowel habit; Psychiatric- mood change
